{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043497","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.725413+00:00","generated_at":"2026-05-24T07:01:23.509020+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"confidence":"high","headline":"CG Oncology reports 75.5% complete response rate in Phase 3 bladder cancer trial; median DOR >28 months","bullets":["83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.","Median duration of response not reached but exceeds 28 months; 46% in CR at 12 months.","No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all expected treatments.","Translational data show no systemic exposure, eliminating need for close contact precautions post-treatment.","Data presented as late-breaking abstract at 40th Annual EAU Congress in Madrid."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043497","json":"https://secwatch.observer/filing/0000950170-25-043497.json","markdown":"https://secwatch.observer/filing/0000950170-25-043497.md","text":"https://secwatch.observer/filing/0000950170-25-043497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/0000950170-25-043497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017025043497/ck0001991792-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T07:01:23.509020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}